DS
CNSP icon

DRW Securities’s CNS Pharmaceuticals CNSP Stock Holding History

DRW Securities’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,429
Closed -$81K – 1367
2025
Q4 		$81K Buy
15,429
+1,379
+10% +$10.3K ﹤0.01% 1085
2025
Q3 		$126K Buy
+14,050
New +$113K ﹤0.01% 1156

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

DRW Securities's CNSP Position: Q1 2026 in Review

DRW Securities sold out of CNS Pharmaceuticals (CNSP) in Q1 2026, closing a stake of 15,429 shares — an estimated $81K sold.

DRW Securities first reported a position in CNSP in Q3 2025 and held it in 2 quarters. The position peaked at $126K in Q3 2025. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2026.

  • DRW Securities reported no remaining CNS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 15,429 CNS Pharmaceuticals shares in Q1 2026, an estimated $81K.
  • DRW Securities first reported a position in CNS Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • DRW Securities's CNS Pharmaceuticals position peaked at $126K in Q3 2025.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.